In CONCERTO-2 , prior non-responders to IFN-based therapy ( N = 106 ) received simeprevir ( TMC435 ) 100 mg QD with PR for 12 ( SMV12 , n = 53 ) or 24 weeks ( SMV24 , n = 53 ) followed by response-guided therapy ( RGT ) with PR for 12/36 ( SMV12 ) or 0/24 ( SMV24 ) weeks .